title: Cervical Cancer Working Group report.
abstract: Disease burden of cervical cancer in Asia was summarized. Human papillomavirus 16 is the most oncogenic human papillomavirus type. Korea's national cervical cancer screening program targets women aged 30 or over, with coverage of almost 80%. Japan has a long history (50 years) of cervical cancer screening, and cytological screening programs have reduced the incidence/mortality of cervical cancer by 70%. But, recent cervical cancer screening coverage is ∼24%. Modeling suggested that vaccination of all 12-year-old girls would reduce cervical cancer cases by 73% in Japan. India has no cervical cancer screening program, as well as a serious lack of awareness in the general population, medical professionals and policy-makers. A realistic, affordable approach would be a low-volume, once-in-a-lifetime human papillomavirus-based screening program. In Australia, the national cervical cancer program has been very successful in reducing the incidence and mortality of cervical cancer. Australia was the first country to implement free, national human papillomavirus immunization (April 2007), expected to reduce human papillomavirus 16 infections by 56% in 2010 and 92% in 2050. A comparison of the UK and Japan was demonstrated that in the UK, cervical cancer screening and human papillomavirus vaccination uptakes are high because the government provides adequate education/funding. The Japanese government needs to put more emphasis on women's health and preventative medicine. Our conclusion and recommendations are that heightened public awareness of cervical cancer prevention, focusing on screening and vaccination will lead to improved survival and a better quality of life.
authors.affiliation: Department of Obstetrics and Gynecology, Jichi Medical University Saitama Medical Center, 1-847 Amanumacho, Ohmiya-ku, Saitama 330-8503, Japan. kryo772007@yahoo.co.jp
authors.forename: Ryo
authors.initials: R
authors.lastname: Konno
authors.forename: Satoru
authors.initials: S
authors.lastname: Sagae
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yoshikawa
authors.forename: Partha Sarathi
authors.initials: PS
authors.lastname: Basu
authors.forename: Sharon J B
authors.initials: SJ
authors.lastname: Hanley
authors.forename: Jeffrey H J
authors.initials: JH
authors.lastname: Tan
authors.forename: Hai-Rim
authors.initials: HR
authors.lastname: Shin
mesh_terms: D000328:Adult; D001208:Asia / Q000453:epidemiology; D002648:Child; D005260:Female; D006801:Humans; D030361:Papillomavirus Infections; D053918:Papillomavirus Vaccines / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D014611:Vaccination
chemical_list: D053918:Papillomavirus Vaccines